Highlights from Akero Therapeutics at AASLD 2025
Akero Therapeutics, Inc. (NASDAQ: AKRO), a pioneering clinical-stage company dedicated to developing revolutionary treatments for serious metabolic diseases, recently announced its participation in the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025. This event is scheduled to occur from November 7-11, 2025, showcasing new findings from the Phase 2b SYMMETRY and HARMONY studies focused on the lead product candidate efruxifermin (EFX).
Oral Presentations Set to Shine
Among the notable presentations, Akero will feature two oral presentations that highlight the efficacy of efruxifermin:
Improvement in Fibrosis Regression
The first oral presentation will detail how efruxifermin is linked to significant improvements in multiple non-invasive tests that indicate fibrosis regression in participants suffering from compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH). This session, led by Dr. Vlad Ratziu, a prominent figure in hepatology, will take place during Clinical Plenary #1 on November 9, 2025.
Portal Hypertension Markers
The second oral presentation will cover findings on how efruxifermin improved markers of portal hypertension in compensated cirrhosis patients, utilizing the Baveno VII criteria. Dr. Mazen Noureddin, an esteemed professor and director, will present these promising results during the MASH Clinical Trials session on the same day.
A Glimpse into Poster Presentations
In addition to oral presentations, Akero will present a poster focused on cutting-edge AI-driven analysis of histological data from the Phase 2b HARMONY study.
AI-Powered Histology Analysis
This poster will explore efruxifermin's impact on liver microarchitecture in patients with pre-cirrhotic MASH. The findings will be presented by Dr. Jörn M. Schattenberg on November 10, 2025, and promise to unveil innovative insights into the treatment of liver diseases.
About Akero Therapeutics
Akero Therapeutics is committed to addressing the needs of patients suffering from metabolic dysfunction-associated steatohepatitis (MASH). Their lead candidate, efruxifermin, is currently undergoing evaluation in three critical Phase 3 clinical studies: SYNCHRONY Histology, SYNCHRONY Outcomes, and SYNCHRONY Real-World. These trials build on the success and learnings from earlier Phase 2b studies, including SYMMETRY and HARMONY.
Contact Information
For further inquiries, interested parties can reach out to Akero's investor contact:
Investor Contact:
Christina Tartaglia
Precision AQ
Phone: 212.362.1200
Email: IR@akerotx.com
For media inquiries, contact:
Media Contact:
Peg Rusconi
Deerfield Group
Phone: 617.910.6217
Email: Peg.rusconi@deerfieldgroup.com
Frequently Asked Questions
What studies will Akero present at AASLD 2025?
Akero will present findings from the Phase 2b SYMMETRY and HARMONY studies on efruxifermin.
Who are the presenters at the oral sessions?
Dr. Vlad Ratziu will present findings on fibrosis regression, and Dr. Mazen Noureddin will present on portal hypertension markers.
What is the significance of the HARMONY study?
The HARMONY study utilizes AI-powered analysis to unveil liver microarchitecture changes in patients with MASH treated with efruxifermin.
What is the purpose of the SYNCHRONY clinical studies?
The SYNCHRONY clinical studies aim to evaluate the safety and efficacy of efruxifermin in a variety of patient populations.
How can I find out more about Akero Therapeutics?
Visit Akero Therapeutics' official website or reach out to their investor relations for more information.
